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Abstract 
Background: Total pancreatectomy with islet auto-transplantation (TPIAT) may be 
performed for patients with unrelenting chronic pancreatitis to relieve pain while 
minimizing the risk of diabetes.  Avoidance of hyperglycemia is essential after TPIAT to 
minimize beta cell apoptosis during islet engraftment.  Closed loop (CL) therapy has 
never previously been investigated in islet transplant recipients but CL devices may 
improve glycemic control within a narrow therapeutic target.  Our objective is to 
determine the feasibility and efficacy of CL therapy to maintain glucose profiles close to 
normoglycemia following TPIAT.   
 
Methods: Here we present analysis of 14 patients (36% male; mean age 35.9±11.4 years-
old).  At the time of transition from IV to subcutaneous insulin (POD=6±1.4 days), 
subjects were block randomized to subcutaneous insulin via a CL pump (n=7) or multiple 
daily injections (n=7) for 72 hours. 
 
Results: Mean serum glucose values were significantly lower in the experimental group 
than in the control group (111±4 mg/dL v. 130±13 mg/dL; p=0.003).  Glycemic 
variability was also lower in the experimental group than in the control group based on 
standard deviation (14.1±3.3 mg/dL v. 21.0±10.2 mg/dL; p=0.115), though was not 
statistically significant.  Hyperglycemia and hypoglycemia AUC were less in the 
experimental group than in the control group, though did not meet criteria for statistical 
significance: 2025±1177 v. 7860±11444 min*mg/dL; p=0.2045 and 146±270 v. 
1615±4267 min*mg/dL; p=0.3813, respectively. 
 
Discussion: Results from this study show that CL therapy is superior to conventional 
therapy in maintaining euglycemia without increased hypoglycemia.  This technology 
shows significant promise as a tool to maintain strict euglycemic targets and minimize 
hypoglycemia after TPIAT. 
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1.0 INTRODUCTION 
1.1 Chronic Pancreatitis 
 Chronic pancreatitis (CP) is an irreversible condition whereby chronic or recurrent 
pancreatic inflammation, fibrosis and scarring damage both the exocrine and endocrine functions 
of the pancreas.  CP is characterized by chronic or recurrent abdominal pain, often leading to 
narcotic dependence and limitations in activities of daily living.  First-line interventions consist of 
medical procedures such as endoscopic retrograde cholangio-pancreatography (ERCP) with 
sphincterotomy, endoscopic balloon dilation, or stent placement.  If these procedures are 
unsuccessful in relieving pain and improving quality of life, then removal of the pancreas, total 
pancreatectomy (TP), may be considered.  Such a procedure however would result in inevitable 
post-surgical diabetes as the insulin producing islet cells would be removed along with the 
exocrine portion of the pancreas.  A simultaneous islet auto-transplantation (IAT) may prevent or 
minimize post-surgical diabetes by restoring all or some of the endocrine function of the excised 
pancreas.  
 The incidence of CP is estimated at around 4 cases per 100,000 person-years and the 
prevalence is about 4 cases per 10,000 persons or a total prevalence of 0.04-5% of the adult 
population 1, 2.  While CP is seen in both genders it is more common in men by a ratio of 4.6:1 3.  
Alcohol has long been identified as the most common cause of CP contributing to 70-80% of 
cases among the adult population 2, 4, 5.  More recently, smoking has become recognized as an 
important independent risk factor and disease modifier providing a synergistic effect with alcohol 
use 3, 4, 6.  The second most common cause of CP is idiopathic pancreatitis.  Hereditary or genetic 
pancreatitis is the third most common cause overall and accounts for a majority of cases in the 
pediatric population 7, 8.  The most common genetic causes are mutations to the cationic 
trypsinogen gene (PRSS1), various Cystic Fibrosis Transmembrane Regulator (CFTR) mutations 
and serine protease inhibitor, Kazal type 1 (SPINK1) mutations 7, 9, 10.  Patients with hereditary or 
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genetic pancreatitis are at particularly high lifetime risk for significant complications including 
37.2% chance of exocrine failure, 47.6% chance of endocrine failure and 44.0% chance of 
pancreatic cancer 10. 
 Initial presentation of pancreatitis is often progressive episodes of recurrent abdominal 
pain.  The disease process can be thought of as a progressive spectrum from acute pancreatitis to 
recurrent pancreatitis to chronic pancreatitis 11.   The pancreatic enzymes of amylase and lipase 
are usually significantly elevated in the acute phases, though their levels may fall with disease 
progression to chronic pancreatitis as fibrotic tissue replaces normal exocrine tissue 2, 5.  
Diagnosis and classification of chronic pancreatitis can be challenging and there exists substantial 
debate in the published literature on the appropriate methods and criteria 12-15.  Frequently used 
imaging modalities include computerized tomography (CT) of the abdomen, magnetic resonance 
cholangiopancreatography (MRCP), ERCP, and endoscopic ultrasound (EUS).  At the University 
of Minnesota (UMN) the diagnosis of CP is made based on clinical history and imaging evidence 
(calcification on CT scan, ductal abnormalities on MRCP or ERCP and/or EUS), and supported 
by genetic confirmation with PRSS1, SPINK1, and CFTR testing in the pediatric population and 
in cases where familial causes are suspected 16. 
 First-line interventions for CP consist of medical management with narcotics and medical 
procedures such as ERCP with sphincterotomy, endoscopic balloon dilation, or stent placement 
11.  In patients for whom these interventions are unsuccessful at relieving pain and improving 
quality of life, TP may be considered to remove the insulting exocrine pancreas  along with 
simultaneous IAT to prevent post-surgical diabetes in a combined total pancreatectomy with islet 
auto-transplantation (TPIAT) procedure. 
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1.2 TPIAT 
 The first ever human TPIAT was performed by Dr. David Sutherland at UMN in 1977 17.  
Since then over 600 TPIAT procedures have been performed at UMN, making it the largest 
center in the world for this highly specialized procedure 18.  Approximately 4-6 TPIAT’s are 
performed per month.  As with all surgical procedures, pre-and post-surgical management plays a 
vital role in producing successful patient outcomes.  Potential candidates for surgery are 
evaluated by a multidisciplinary team using the published UMN criteria for TPIAT (Table 1.) 16.   
 
Table  1. University of Minnesota Criteria for Total Pancreatectomy and Islet Auto-
Transplantation16 
 
 
 The surgical procedure for TPIAT may vary by case, but generally involves partial 
duodenectomy, Roux-en-Y duodenojejunostomy, choledochojejunostomy, and splenectomy as 
described in previous surgical literature from UMN (Figure 1.A.) 19-23.  TP is performed in such a 
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way that the blood supply to the pancreas is preserved until just prior to removal to minimize 
warm ischemic time to the islets 22.  In addition patients receive a cholecystectomy and 
appendectomy if not previously done.  Patients also generally receive gastric and jejunal (G-J) 
tube placement for post-surgical trans-pyloric feeding. 
 
Figure 1. A. Total Pancreatectomy Surgical Procedure  involving involves partial duodenectomy, 
Roux-en-Y duodenojejunostomy, and choledochojejunostomy 21; B. Total Pancreatectomy with 
Islet Auto-Transplantation involving islet isolation and infusion into the portal vein 23 
 
 
Following removal of the pancreas, a collagenase-based enzyme solution is used to digest the 
exocrine pancreas, and the remaining islets are harvested via an automated method.  The islets are 
then infused back into the portal vein where they engraft in the liver sinusoids (Figure 1. B.). 
 Immediately following surgery, patients are started on an intravenous (IV) insulin infusion, 
titrated to maintain blood glucose (BG) in a narrow range of 80-125 mg/dL.  Post-surgical 
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feeding is begun via Jejunal-tube (J tube) around post-op day #1 at a trophic rate and then titrated 
up to goal rate gradually as clinically tolerated.  Patients are transitioned from IV to subcutaneous 
(SQ) insulin once they are stable at their goal feeding rate. 
 Outcomes after TPIAT have been reported in the literature from UMN after >400 
successful cases were performed 22.  Pain-improvement was reported in 85% of patients with 59% 
ceasing narcotic use by 2 years post-surgery.  Significant quality of life improvement was shown 
from baseline in all dimensions of function.  At 3 years post-surgery 30% of patients were 
insulin-independent with an additional 33% having partial islet function.  While no single factor 
is predictive of insulin independence, islet equivalents (IEq) transplanted has been shown to be 
the main predictor of future insulin independence 19.  Among patients from UMN, insulin 
independence at 1 year post-transplant was observed in 63% of patients receiving > 5000 IEq/kg, 
27% of those receiving 2501-5000 IEq/kg and 7% of those receiving ≤ 2500 IEq/kg. 
 
1.3 Islet Engraftment 
 During islet isolation, purification and harvesting, islets are stripped of their native 
arteriolar blood supply.  In the immediate post-transplant period, islets are reliant on diffusion of 
nutrients and oxygen to the islet core until neovascularization is complete, a process that may take 
weeks to months 24, 25.  During this engraftment period, the transplanted islets are especially 
vulnerable to overstimulation by hyperglycemia in an anoxic environment, which contributes to 
beta-cell loss 26, 27.  Studies in animal models have demonstrated that hyperglycemia increases 
beta-cell apoptosis, while maintenance of narrow-range euglycemia reduces the IEq necessary to 
prevent post-surgical diabetes 28-33.  Data from a large TPIAT cohort at UMN further supports 
these experimental findings by showing that small differences in mean blood glucose in the first 
week post-transplant correlate with later insulin independence 34. 
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1.4 Insulin Pump Technology and Closing the Loop 
 Use of portable subcutaneous insulin infusion pumps first became possible in the late 
1970’s, with early studies showing the possibility of improved glycemic control with this 
technology 35.  With the publication of the primary results from the Diabetes Control and 
Complications Trial in 1993 36, there was renewed focus on the importance of maintaining near-
normal blood glucose control and reducing hemoglobin A1c to minimize the potential for micro 
and macrovascular complications.  However achievement of these glycemic parameters came at 
the cost of increased frequency of hypoglycemic events.   
 Over the next decade this shift in care promoted commercial development of synthetic 
insulin analogues for improved multiple daily injection (MDI) therapy such as long-acting insulin 
glargine (Lantus) and rapid-acting insulin aspart (Novolog) and insulin lispro (Humalog).  During 
this same period there was rapid expansion in interest and design of feasible Continuous 
Subcutaneous Insulin Infusion (CSII) systems which gained wide-spread commercial acceptance 
in the late 1990’s and early 2000’s as early research supported improved outcomes with pump 
usage 37. 
 The concept of a mechanical artificial pancreas (AP) has followed development of CSII 
technology.  Such a system would involve the components of a continuous insulin delivery 
device, glucose sensor, control tool decision algorithm(s) and any additional devices necessary 
for communication between these components.  This type of approach would allow for automated 
control of blood glucose levels, minimizing periods of hyperglycemia but also importantly 
reducing the risk for hypoglycemia.  While there have been those in the research community with 
interest in intravenous sampling of blood glucose and/or delivery of insulin, the majority of 
doctors in the clinical community view a subcutaneous approach for SQ BG sensing and insulin 
administration as the only reasonable option likely to gain widespread patient acceptance and 
usage.  This view fueled the development of Continuous Glucose Monitoring (CGM) devices 
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during the 1980’s and 1990’s with first commercial approval of a CGM device in 1999 38-41. 
 In 2006, the Juvenile Diabetes Research Foundation (JDRF) Artificial Pancreas project 
outlined a step-wise roadmap to development, refinement and regulatory approval of a SQ/SQ AP 
system (Figure 2.) 42.  This roadmap describes successive steps from sensor augmented pump 
(SAP) therapy, first generation systems involving sensor assisted therapy at BG extremes, second 
generation systems of hybrid and full closed loop therapy and possible third generation systems 
of multi-hormone (e.g. insulin and glucagon) therapy 43. 
 
Figure 2.  Juvenile Diabetes Research Foundation Artificial Pancreas Project Roadmap 42 
 
 
 At the present time a step-1 commercial device (the Medtronic 530g system) with 
Threshold Suspend (TS) is available in the United States for patients with overnight 
hypoglycemia and a recent phase 4 study shows that this system is successful in reducing 
overnight hypoglycemic events without producing rebound hyperglycemia 44.  A step-2 
commercial device (the Medtronic 640g system) with predictive low-glucose suspend was 
recently approved by the FDA and will be available to patients by the end of 2015.  Initial studies 
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on this technology have shown substantial reduction in overnight hypoglycemia 45, 46.  Step-3 
devices with combined hypoglycemia and hyperglycemia minimizers are currently under phase 3 
study 47. 
 Second and third generation devices consisting of hybrid closed loop systems, fully 
automated closed loop systems and dual-hormonal systems are all under development at various 
stages of clinical testing at roughly a dozen centers around the world.  The pathway to 
commercial approval for these advanced devices generally occurs in the steps of in silico testing 
using computer based compartment models of glucose response to insulin, followed by testing in 
hospitalized patients, followed by testing in controlled environment outside the hospital, and 
finally testing in the home and outpatient environments.  Closed loop systems also generally 
perform better during periods of fasting (such as overnight) and still have difficulty with the 
glycemic excursion of unannounced meals. 
 Current research on CL systems demonstrates an overall common theme of successful 
control of overnight BG with values in target range 70-100% of the time and marked difficulty 
preventing post-meal glycemic excursions with unannounced meals.  An excellent summary 
article of CL research was recently published by Garg and colleagues 48.  Additional recent 
studies of importance to the current project are presented below (Table 2.). 
  
 9 
Table 2. Summary of Recent Diabetes Technology Studies 
Authors Subjects Control Type Setting Meals Findings 
Breton et al. 
(2012) 49 
38 
Control to 
Range (MPC) 
Hospital Yes 
Increased time near normoglycemia from 61 to 74%, 
reduced hypoglycemia 2.7 fold, improved meal BG without 
increasing hypoglycemia and achieved 97% near 
normoglycemia overnight. 
Brown et al. 
(2015) 50 
10 DiAs (MPC) Outpatient No 
CL control overnight significantly improved time in range, 
reduced mean BG in the AM and overnight and resulted in 
better control the next day. 
Cameron et al. 
(2014) 51 
10 
MMPPC 
(MPC) 
Hospital Yes 
With meals the controller maintained reasonable glycemic 
control with only one controller-induced hypoglycemic 
event. 
Chase et al. 
(2014) 52 
53 MPC Hospital Yes 
The AP handled 4 different bolus types safely but at the 
expense of having elevated post-prandial BG  in most 
subjects. 
Elleri et al. 
(2012) 53 
8 MPC Hospital No 
Overnight BG levels were within range 82% of the time 
when the system was started at 18:00 hours and 64% of the 
time when started at 21:00 hours. 
Elleri et al. 
(2013) 54 
12 MPC Hospital Yes 
CL control increased time in target range compared to 
conventional pump therapy (84% v. 49%, p=0.02) without 
increasing hypoglycemia. 
Kovatchev et al. 
(2014) 55 
20 DiAs (MPC) Outpatient Yes 
CL control reduced hypoglycemia and hypoglycemic 
treatments compared to SAP therapy.  There was a marginal 
increase in average BG. 
Leelarathna et al. 
(2014) 56 
enrolling MPC Outpatient Yes 
Outpatient study comparing CL control v. SAP therapy for 3 
months.  Will aim for 30 participants. 
Ly et al. (2014) 57 32 DiAs (MPC) Outpatient No 
Overnight study at diabetes camp. Median percent time in 
range was 73% in CL group and 52% for SAP group.  Less 
time in hypoglycemia for CL group than SAP group. 
Nimri et al. 
(2014) 58 
24 
MD-Logic 
(FL) 
Outpatient No 
CL nights significantly reduced time spent in hypoglycemia 
and increased time spent in target range compared with SAP 
therapy. 
O'Grady et al. 
(2012) 59 
8 PID Hospital No 
Time in target range was significantly greater for CL night 
than open-loop nights.  Hypoglycemia was also reduced. 
Thabit et al. 
(2015) 60 
40 MPC Outpatient No 
Used CL overnight and SAP therapy during the day.  
Improved % time in target with CL therapy compared to 
control.   CL reduced mean BG with no change in variability 
(SD).  Both hyperglycemia and hypoglycemia were reduced. 
Zisser et al. 
(2014) 61 
53 MPC Hospital Yes 
Control-to-range system performed better overnight than 
during the day with difficulty preventing post-meal BG 
elevation. 
 
1.5 Control Tool Algorithms 
 A fundamental aspect of any artificial pancreas system is the control algorithm responsible 
for making dynamic insulin dosing adjustments in real-time.  The theory for  artificial pancreas 
algorithms arises from the discipline of control theory and dynamical systems 62.  Control theory 
arises from fundamental ideas in mathematics and is a fundamental tool in many engineering 
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disciplines including Aerospace, Mechanical, Chemical, Electrical and Computer Engineering.  
An excellent comprehensive review of the engineering of  AP algorithms was recently published 
by Doyle and colleagues in Diabetes Care 63.  
  Different groups around the world are developing 3 different control systems for CL 
therapy: proportional-integral-derivative control (PID), model predictive control (MPC), and 
fuzzy logic control (FL).  PID control is probably the most basic form of a control system.  It 
calculates proportional error (present error), integral error (past error) and derivative error 
(predicted future error) and then utilizes a weighted sum to determine insulin dose for that minute 
64, 65.  MPC relies on the development of a complex multi-compartment model via a series of 
differential equations.  This model is then used to predict the appropriate dosing action for a fixed 
time interval (e.g. 15 minutes) after which time the system is reassessed and the appropriate 
model selected for the next time interval 66.  FL control utilizes a series of “fuzzy” logical 
decision rules that mimic a human decision maker to make reasoned decisions on diabetes 
treatment in a manner similar to how a practitioner thinks 67. 
 The present study utilizes Medtronic’s ePID (external physiological insulin delivery) 2.0 
controller 64, 65, 68.  This controller uses a modified PID controller with a term for insulin feedback 
(IFB) previously described in detail by Ruiz et al. working with the engineers from Medtronic 68.  
Sensor glucose levels at time  (()) are calculated based on a calibration factor (CF; 
mg/dL/nA) estimated from a linear regression of plasma glucose and filtered sensor current with a 
fixed sensor delay time of 10 minutes to account for delayed BG shifts between the intravenous 
and interstitial compartments 69, 70. 
  () =  ∗  ()        (1) 
 
The PID portion of the ePID 2.0 controller utilizes a series of equations outlined below: 
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  () =  [() − ]        (2) 
  () = ( − 1) +  

 !
∗ [() − ]      (3) 
  "() =   ∗  # ∗  
∆%(&)
∆
        (4) 
  "() = () + () + "()       (5) 
Where  is set individually based on the patient’s total daily insulin requirement ( ##; U/day): 
   =  
'())∗*+
,+∗-.++
          (6) 
 
The integral time constant (') was set at 250 and the derivative time constant (#) was set at 50.  
In these equations,  and  − 1 denote the most recent time value and the value 1 minute 
previously, respectively.  The term 
∆%(&)
∆
 denotes the rate of change of SG.  The target BG () 
was set by the investigators at either 100 or 110 mg/dL based on clinical situation.   
 The IFB term comes from the following equations: 
  %/() =  0-- ∗  %/( − 1) + 1- ∗ #( − 1)     (7) 
  2() =  03- ∗ %/( − 1) + 033 ∗  2( − 1) +  13 ∗ #( − 1)  (8) 
  4() =  05- ∗  %/( − 1) + 053 ∗ 2( − 1) + 055 ∗ 4( − 1) + 15 ∗ #( − 1) (9) 
  6() =  7- ∗ %/() + 73 ∗ 2() +  75 ∗  4()    (10) 
 
Here, real-time estimates of subcutaneous insulin (%/), plasma insulin (2), and 
interstitial/effective insulin (4) concentrations are dependent on one another, scaled using 
varying 0 coefficients and are dependent on insulin delivery (#).  Insulin delivery (#) at time  
is then determined by the final equation: 
  #() = (1 + 7- + 73 + 75) ∗ "() − 6()     (11)  
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1.6 Potential Impact of the Work on Health 
 The present study involves several elements of innovation with potential to significantly 
impact health.  This study represents the first use of closed loop insulin technology in an islet 
transplant population.  Demonstration of the ability to safely and effectively achieve ambitious 
glycemic targets in this population is an important first step towards regulatory approval and 
clinical acceptance of this new technology.  The benefits of narrow range euglycemic control in 
the post-TPIAT period are improved islet engraftment and long term survival with corresponding 
decreased long term insulin requirements. 
 In addition to the potential benefits for the CP population, this work may have impact on 
the larger type 1 diabetes population.  Islet auto-transplantation in CP patients involves a patient 
with a non-autoimmune condition receiving their own (human) islets following pancreatic 
removal.  In this situation there is no underlying auto-immunity, and no risk for allo-immune or 
xeno-immune reaction as would be seen for a patient receiving cadaveric donor or porcine donor 
islets.  TPIAT therefore provides a unique human model for the mechanics of islet transplantation 
and engraftment which lacks auto-, allo-¸ or xeno-immunity as well as potential toxicity from the 
medications used to modulate immunity.  This population thus presents a novel opportunity to 
refine the mechanical aspects of islet transplantation with potential to benefit additional patient 
populations which may require allo- or xeno-grafts to correct their underlying conditions. 
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2.0 METHODS 
2.1 Pre-Study Objectives and Hypotheses 
 The following objectives, specific aims and hypotheses were outlined a priori as part of the 
grant applications, FDA application, IRB application and study protocol. 
Objectives: 
The overall objective of this pilot study was to determine the feasibility and efficacy of closed 
loop (CL) insulin pump therapy to maintain glucose profiles close to normoglycemia following 
islet auto-transplantation, during the critical period of islet engraftment.  Such a therapy would be 
beneficial in reducing hyperglycemia-induced beta cell apoptosis and thereby may improve long-
term islet transplant outcomes.  The primary objective of the pilot proposal was to demonstrate 
that closed loop pump therapy is superior to conventional subcutaneous insulin at maintaining 
target blood glucose early after IAT, and to gather preliminary outcomes data on islet function.   
The results of this study may also be used to plan and support an NIH grant proposal for a larger 
clinical trial. 
Specific Aims: 
Specific Aim #1:  To determine if use of a closed loop insulin system can successfully achieve 
tighter glycemic control compared to conventional injection regimens in the early post-transplant 
period.  To investigate this aim, 20 patients will be randomized 1:1 to receive either (1) closed 
loop pump therapy for 72 hours or (2) standard insulin injection therapy plus a continuous 
glucose monitor sensor for data collection at the time of transition from intravenous to 
subcutaneous insulin (~1 week post-transplant).   
Hypothesis 1:  The mean blood glucose will be lower in the closed loop pump group than 
in the group receiving conventional therapy. 
Hypothesis 2:  There will be less glycemic variability in the closed loop pump group, as 
evidenced by lower standard deviation in blood glucose  
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Hypothesis 3: There will be less time spent in hyperglycemia (>140 mg/dL) and 
hypoglycemia (<70 mg/dl) in the closed loop pump group. Area Under the Curve (AUC) 
above 140mg/dl and AUC below 70mg/dl will be less in CL group.  
 Specific Aim #2:  To collect preliminary data on insulin requirements and islet function in the 
first 6 months post-transplant in the closed loop pump and conventional therapy group.  Although 
the duration of closed loop pump therapy in this initial pilot study is short, evidence of reduced 
insulin use and/or higher C-peptide secretion at 6 months post-transplant in this pilot analysis 
would provide powerful evidence to support a larger trial and a prolonged duration of treatment. 
Hypothesis 4:  Insulin requirements (units/kg/day) will be lower and stimulated C-peptide 
levels from mixed meal testing higher in the closed loop pump group. 
 
2.2 Patient Population 
 Participants for the study were patients with chronic pancreatitis being seen by surgeons at 
the University of Minnesota for evaluation for TPIAT.  Potential subjects were approached by a 
trained member of the study team during part of their multidisciplinary pre-transplant evaluation.  
Patients were provided with an approved information sheet and sample consent forms for 
independent review.   
 Inclusion criteria for participation in the clinical trial were (1) age 21 to 64 years old and 
(2) undergoing total pancreatectomy and islet auto-transplantation.  Exclusion criteria for 
participation in the trial were (1) preexisting diabetes as defined by ADA criteria for diagnosis of 
diabetes 71, (2) use of acetaminophen during the 72 hour investigational period due to this 
medication falsely impacting CGM sensor values, (3) any medical condition requiring 
corticosteroids, (4) severe psychiatric disease or developmental delays that might interfere with 
ability to provide informed consent, and (5) any other medical condition which in the opinion of 
the investigators impairs the person’s ability to safely participate in the trial. 
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 Informed consent was obtained during face-to-face consultation with a trained member of 
the study staff at a separate consent visit during the pre-transplant workup and prior to surgical 
intervention.  Patients were given informational materials and consent forms for review prior to 
this visit.  They were given ample opportunity to ask questions of study staff and all materials 
were reviewed face-to-face prior to signing any documents.  They were informed that 
participation was optional, they may withdraw consent at any time and failure to participate 
would not adversely affect their care in anyway. 
 The clinical trial involved use of an experimental, non-commercially approved medical 
device in adult patients after surgery for dynamic control of blood glucose.  As such, the trial 
required review and approval by both the University of Minnesota Investigational Review Board 
(IRB) and the United States Food and Drug Agency (FDA).  FDA approval was obtained on 
August 2nd, 2013 (FDA ID G130178).  UMN IRB approval was obtained on October 16th, 2013 
(IRB ID 1307M37923).  The trial was also registered with clinicaltrials.gov on September 19th, 
2013 (ID NCT01945138). 
 
2.3 Randomization 
 Randomization was performed between the time of informed consent and the day of 
TPIAT surgery.  Participants were block randomized 1:1 to receive subcutaneous insulin via 
either closed loop insulin pump (experimental arm) or multiple daily injections (control arm).  A 
computer based random number generator was used to generate random number schedules.  First, 
a random number 1-2 was generated with the number 1 representing block size of 2 and the 
number 2 representing a block size of 4.  Then non-repeating random numbers 1-2 or 1-4 were 
generated based on the block size with odd numbers representing the experimental arm and even 
numbers representing control arm.  A total of 20 assignments were made for each schedule with a 
1:1 control to experimental ratio.  A total of 5 randomization schedules were prepared.  A 
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physician not otherwise involved with this study was then asked to randomly upload one of the 5 
schedules to the randomization module of REDCap.  The secure REDCap database was used to 
house the randomization schedule and to generate the study arm assignment at the time of 
randomization. 
 
2.4 Timing of Study Visits 
 Potential participants were first contacted during their pre-transplant evaluation.   As part 
of their routine TPIAT workup participants had a pre-surgical visit at which time baseline labs of 
hemoglobin A1c, and mixed meal tolerance test (MMTT) with BG and c-peptide levels were 
obtained (Table 3.).  Interested patients were then brought in for a separate consent visit where 
inclusion and exclusion criteria were reviewed and informed consent was obtained.  
Randomization was conducted between the time of informed consent and the day of TPIAT 
surgery.  Inclusion and exclusion criteria were reviewed on the day of surgery to ensure that the 
performed procedure fit with the study definition of TPIAT.  Exclusion criteria were again 
reviewed prior to beginning SQ therapy to ensure that patients were not on acetaminophen or 
steroids and were stable enough for study participation.   
 
Table 3. Timing of Endpoint Assessment by Study Visit. 
Visit Hb 
A1c 
MMTT C-Peptide BG CGM 
Data 
YSI BG 
Values 
Insulin 
Req 
Pre-Surgical x x x x    
72h Post-Op   x x x x x 
14&28d Post-OP   x x    
6 month f/u x x x x   x 
 
 
 When participants reached target continuous J-tube feeds, generally 1 week after surgery, 
they were converted to either MDI + CGM (control) or CL insulin (experimental) therapy for 72 
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hours.  During this period both groups were evaluated for AM c-peptide and BG levels, q4h 
reference BG levels (average and standard deviation), CGM BG levels (average, standard 
deviation, hypoglycemia AUC and % time, and hyperglycemia AUC and % time), and average 
daily insulin requirements.  Participants were also seen for 14 and 28 day post-surgical follow up 
visits for random c-peptide and laboratory serum glucose evaluation.  Participants were then 
evaluated at 6 months post-TPIAT for laboratory evaluation of hemoglobin A1c, mixed meal 
tolerance test (serum glucose and c-peptide), and current insulin requirements. 
 
2.5 Study Endpoints 
Blood Glucose Values:  Blood glucose values were obtained by frequent bedside testing every 30 
minutes (± 15 min) during the 72 hour investigational period for the study group, or more often as 
needed for hyperglycemia or hypoglycemia (as described in safety plan).  Testing was performed 
using a YSI (Yellow Springs Instrument) 2300 STAT Plus Glucose Analyzer.  The control group 
(not on CLP) had blood glucose measured every 4 hours over the 72 hour study period at standard 
time points (0001, 0400, 0800, 1200, 1600, 2000; ± 15 min) for comparison as would be standard 
for routine clinical care.  Values computed from this data were the primary endpoint markers 
of glycemic control: mean blood glucose and standard deviation in blood glucose.  
 
Continuous glucose monitoring (CGM):    Participants in both groups wore 2 continuous glucose 
monitoring sensors provided by Medtronic for the 72 hour study period.  This data serves as a 
secondary endpoint with the statistics of average sensor BG, standard deviation in sensor 
blood glucose and hyperglycemic markers of AUC in hyperglycemia (BG >140 mg/dL) and 
percent time in hyperglycemia (BG>140 mg/dL) and the hypoglycemic markers of AUC in 
hypoglycemia (<70 mg/dL) and percent time in hypoglycemia (BG<70 mg/dL). 
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Two Hour Mixed Meal Tolerance Test (MMTT):  This protocol has been validated as a sensitive 
indicator of endogenous insulin production 72.  Glucose and C-peptide were drawn at baseline 
and every hour for 2 hrs. The patients were given Boost HP 6 cc/kg (max 360 ml), ingested 
within 5 min, after the time 0 blood draw.  This test was performed at the pre-transplant visit and 
at the 6 month follow-up visit as part of the patient’s routine transplant care. 
 
Insulin Use:  Total daily insulin requirements were calculated as average total daily dose (TDD) 
of insulin (U/day) and TDD per unit body weight (U/kg/day) over the 72 hour investigational 
period.  Current insulin requirements were also reviewed at the 6 month follow up visit as TDD 
and TDD per kg. 
 
Hemoglobin A1c Values (A1c):  A measure of average serum blood glucose over the previous 3 
months, hemoglobin A1c measurement has become standard of care for monitoring diabetes 
control and compliance with therapy.  It has recently been added to the diagnostic criteria for 
diabetes.  It was measured at the pre-transplant visit to validate that the participant did not have 
pre-existing diabetes.  Hemoglobin A1c was also measured at the 6 month follow-up visit as part 
of the patient’s routine post-transplant care, and was used to compare the glycemic status of the 
study and conventional therapy groups. 
 
C-Peptide Values:  C-peptide is an inert polypeptide which is cleaved from insulin as part of 
endogenous insulin production, but which is lacking in commercially produced insulin.  It is used 
as a marker of endogenous insulin production.  In TPIAT patients C-peptide levels correlate with 
successful graft function.  C-Peptide levels were obtained an all study participants at the pre-
transplant visit (as part of the MMTT), daily during the 72 hour intervention period, at the 14 and 
28 days post-transplant visits, and at the 6 month follow-up visit (as part of the MMTT).   
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2.6 Total Pancreatectomy and Islet Auto-Transplantation Procedure 
 All participants underwent Total Pancreatectomy consisting of partial duodenectomy, 
Roux-en-Y duodenojejunostomy, choledochojejunostomy, and splenectomy as described in 
previous surgical literature from UMN 19-21 (Figure 1.A.).  Isolation and purification of the 
patient’s own islet cells was performed in the University of Minnesota Molecular and Cellular 
Therapeutics GMP Facility.  Using a pressure-controlled pump system, the pancreas was 
distended with cold enzyme solution 73.  The pancreas was then digested using the semi-
automated method described by Ricordi 74.  The islets were then infused into a tributary of the 
portal vein, or if elevated portal pressures prevented infusion of all the islets intraportally, the 
remaining islets were transplanted into the peritoneal cavity (Figure 1.B). 
 Immediately after surgery all patients were started on a continuous intravenous (IV) insulin 
infusion protocol (IIP) with the goal of maintaining BG in the range of 80-125 mg/dL.  This 
protocol is similar to the pediatric IIP recently published by our group 20.  The protocol is an 
electronic medical record-based protocol which addresses the recommended IIP elements of: 
frequent BG checks, use of current as well as previous BG values in determining insulin rate 
adjustments, use of rate of change in BG level in determining insulin rate adjustments, 
protocolized nurse-directed decisions, and minimizing hypoglycemia.  As with all TPIAT 
patients, participants in this study were kept on the IIP from the completion of surgery until they 
reached goal J-tube feeds. 
 After surgery all patients were started on trophic J-tube feeding on post-op day 1.  Trophic 
feeding is generally started at a rate of 10 mL/hr with an adult liquid formula such as Impact 
Peptide 1.5 Cal/mL or Peptamen 1.5 Cal/mL as advised by the Registered Dietitian and 
determined by Transplant Surgery service.  Feeds were then gradually advanced to the goal rate 
advised by the Registered Dietician and as tolerated by the patient with final decision making 
resting with the Transplant Surgery team; a process which generally takes 4-8 days.  Once 
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patients were determined to be stable on their goal feeding rate, they were transitioned to SQ 
insulin therapy per their random group assignments for the 72 hour investigational period.  
Patients were kept on continuous J-tube feeding at their goal rate throughout the study period.  
Patients did not have any PO intake through the end of the study period. 
 
2.7 Subcutaneous Insulin Investigational Period 
 Participants randomized to the control arm (Multiple Daily Injection insulin therapy) 
received SQ insulin therapy per standard post-TPIAT protocol as directed by the primary 
endocrinology team, without influence or input by the research team.  Insulin dose determination 
and adjustments were made by the adult endocrinologist, endocrinology fellow, or diabetes 
ARNP, as would generally be done had the patient not participated in the study.  Participants in 
the control group received long-acting insulin, either glargine (Lantus) or detemir (Levemir), 
calculated  based on the total daily IV insulin rate at stable enteral feeds, split into one or two 
doses a day.  BG was monitored every 4 hours by bedside glucometer and rapid-acting insulin 
aspart (Novolog) was given as a correction every 4 hours as needed for BG levels > 125 mg/dL 
with sensitivity determined by patient’s daily insulin requirements.  The long-acting insulin dose 
was adjusted as needed based on daily correction requirements.  During this time period, trained 
study staff obtained q4h YSI reference BG values and daily AM C-peptide and BG values.  
Participants also wore 2 CGM devices (1 primary and 1 backup).  These devices did not provide 
real-time data and the results were reviewed only after the 72 investigational period for 
comparison with the experimental group. 
 Participants randomized to the experimental arm received SQ insulin as directed by the 
Medtronic ePID 2.0 Control Tool system.  Participants in this group wore a Medtronic Paradigm 
REAL-Time Insulin pump loaded with insulin aspart (Novolog) as well as two Enlite Glucose 
Sensors attached to MiniLink REAL-Time Transmitters (Figure 3. and Table 4.).   
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Figure 3.  Medtronic ePID 2.0 System Patient Diagram (I.) and Concept Diagram (II.).  Letters 
correspond to component descriptions in Table 4. 
 
Table 4.  Devices used in the ePID 2.0 System.  Letters correspond to components in Figure 3. 
 Generic Name Device Name Model Number Device Description Approval Status 
A Insulin Pump Medtronic 
Paradigm REAL-
Time Insulin 
Pump 
MMT-722 
 
 
Ambulatory, battery operated, rate-
programmable infusion pump designed to 
deliver insulin from a reservoir.  
The reservoir is driven by a motor. 
Commercially 
available 
 
B Subcutaneous 
glucose sensor 
Enlite Glucose 
Sensor 
MMT-7008X Single-use, disposable sensor designed to 
continuously monitor interstitial glucose 
concentrations for up to 6 days.   It is 
inserted into the subcutaneous tissue of the 
user and connected to a transmitter device. 
Commercially 
available  
 
 
C Transmitter MiniLink REAL-
Time Transmitter 
(modified to 
transmit every 
minute) 
MMT-7703XNA Provides power to the sensor and measures 
the sensor signal current that is converted to 
a digital signal, and is filtered to reduce 
noise artifact.  The digital signal is then 
transmitted to a receiving device 
(Medtronic Paradigm insulin pump) via 
radio frequency (RF) once every 1 minute. 
Investigational 
 
 
D Control Tool 
software 
Control Tool 
Software, version 
5.1 that is housed 
on a laptop 
NA The control tool software houses the Closed 
Loop algorithm that calculates an insulin 
dose based on  information received from 
the insulin pump and/or transmitter 
Investigational 
 
 
E Signal 
Transceiver 
ComLink  MMT-7304NA Sends messages from the Control Tool 
software to the pump and sends messages 
from the pump or transmitter to the Control 
Tool software 
Commercially 
available 
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The participants stable total daily dose of IV insulin and IV insulin rate were used by the custom 
made Medtronic TPIAT Gains Calculator to determine the parameters for initial controller 
settings (Table 5.). 
Table 5. Default Parameter Settings and ranges for the ePID 2.0 System 
Parameter Nominal Value Lower Bound Upper Bound 
Controller gain:  
8 =  
 ## ∗ 60
90 ∗ 1500
 0.5 ∗ 8  1.2 ∗ 8 ∗ (1 +
1
6
(7- + 73 + 75)) 
Integral time constant: '  250 100 750 
Derivative time constant: # 
50 
40 (normal) 
0 (hypoglycemia) 100 
ISC feedback gain: 7- 0.64935 0 6.0 
IP feedback gain: 73 0.34128 0 6.0 
IEFF feedback gain: 75 0.0093667 0 6.0 
Target glucose (set point):   100-110 90 120.0 
 
-  ## is the total daily insulin dose (U/day).  The controller gain varies based on the total amount of exogenous insulin required by the 
individual patient.  Subtle fluctuation in BG requiring frequent adjustment in the basal delivery of insulin is achieved by adjusting the 
derivative time constant (#) and the integral time constant (') to suite glycemic control during the continuous J-tube feeding period. 
 
During the 72 hour investigational period participants in the experimental group had their SQ 
insulin infusion rate adjusted every minute based on the control tool algorithm.  YSI BG values 
were obtained q30 minutes or more frequently as required by the safety protocol.  Insulin rate, 
CGM BG values and YSI BG values were presented in real-time on the Control Tool software for 
review by trained study staff.  Participants in this group also had reference q4h YSI BG values 
collected for comparison with the control group.  In addition, these participants also had AM C-
peptide and BG values collected.  At the end of the investigational period, CGM data was 
extracted from the Control Tool for analysis. 
 
2.8 CGM Analysis 
 This study marked the first clinical trial using the Medtronic Enlite 2 subcutaneous glucose 
sensors as part of a closed loop system.  It was also one of the first studies to use CGM in a post-
surgical patient population and in patients with some level of endogenous islet function.  
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Transient abdominal and peripheral edema was anecdotally observed by the researchers during 
the pilot study with possible low signal strength as a result.  The study protocol called for sensor 
recalibration for 2 values in a row with an absolute relative difference (ARD) of ≥20% or one 
value with an ARD of ≥ 30%.  Device recalibration and switching of the active sensor was also 
permissible at the investigator’s subjective discretion.  To evaluate CGM performance in this 
pilot study a post hoc analysis of was conducted of CGM bias, mean absolute relative difference 
(MARD), calibration values, recalibration frequency, active sensor changes, and Clarke Error 
Grid analysis75, 76. 
 
2.9 Data Analysis 
 Study data were collected and managed using REDCap electronic data capture tools hosted 
at UMN 77.  REDCap (Research Electronic Data Capture) is a secure, web-based application 
designed to support data capture for research studies, providing 1) an intuitive interface for 
validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) 
automated export procedures for seamless data downloads to common statistical packages; and 4) 
procedures for importing data from external sources.  All analyses were performed using SAS 
version 9.3 (Cary, NC).   
 Data are presented as mean ± standard deviation or as percentage (95% confidence 
interval), except where otherwise noted.  Hypothesis testing was conducted using two-
sided Student’s t-test with equal variance. Values of p ≤0.05 were considered statistically 
significant.  AUC for CGM analysis of experimental and control patients was determined via 
Riemann sums method with width of 5 and 1 minutes, respectively.  Analysis for confounding 
and effect modification was conducted using multiple least-squares linear regression.  Clarke 
Error grid analysis was conducted using standard regional bounds defined by Clarke et al 75, 76. 
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3.0 RESULTS 
3.1 Patient Population, Demographics and Pre-Transplant History 
 In total 21 patients who met initial recruitment criteria and were consented for possible 
study participation (Figure 4.).  Of these, 7 patients were not subsequently started on study 
protocol due to canceled surgery in 2 patients, only partial completion of surgical procedure in 2 
patients, post-surgery complications in 2 patients and withdrawal of consent in 1 patient.  Of the 
patients who met inclusion and exclusion criteria at the time of SQ transition 7 patients were 
randomized to the experimental arm and 7 were randomized to the control arm. 
 
Figure 4. Study Recruitment, Enrollment and Randomization 
 
 Within the entire study cohort there were 5 men and 9 women with an average age of 
35.9±11.4 years-old.  Demographic characteristics of age, weight at transplant, and BMI at 
transplant were not significantly different between the two study groups (Table 6.).  Primary 
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etiology of CP was roughly evenly distributed between the two groups.  Pre-transplant values of 
hemoglobin A1c, fasting BG, fasting C-peptide, and peak MMTT C-peptide were also not 
significantly different between groups.  The islet yield transplanted was quite high overall 
(5432±2983 IEq/kg) and was not significantly different between the two study groups.  The time 
between surgery and SQ transition (Days on drip) was significantly shorter for the experimental 
group than for the control group (5.1±1.1 days v. 6.9±1.1 days; p=0.011).  These surgical factors 
(Islet Yield and Days on Drip) will be more thoroughly explored in the following sections. 
 
Table 6. Demographic and Baseline Patient Characteristics (* indicates statistical 
significance with p < 0.05) 
  Control Group Experimental Group p-value 
Age (yrs) 33.1 ± 13.3 38.6 ± 9.4 0.394 
 Sex M/F (% male) 4/3 (57%) 1/6 (14%) 
  Wt at Tx (kg) 76.7 ± 23.7 66.1 ± 10.3 0.298 
 BMI at Tx (kg/m2) 24.9 ± 5.7 25.3 ± 4.5 0.899 
 Hemoglobin A1c (%) 5.4 ± 0.5 5.1 ± 0.2 0.132 
 Fasting BG (mg/dL) 95 ± 13 89 ± 6 0.308 
 Fasting C-peptide (ng/mL) 3.0 ± 3.7 2.0 ± 0.6 0.543 
 Peak MMTT C-peptide (ng/mL) 5.8 ± 4.4 6.4 ± 2.2 0.740 
 Islet Yield (IEq/kg) 4245 ± 2174 6619 ± 3357 0.142 
 Days on drip (days) 6.9 ± 1.1 5.1 ± 1.1 0.011 * 
Primary Etiology of CP         
Identified Genetic Mutation  
(PRSS1, SPINK1, CFTR) 
1  (14%) 3  (43%)   
Mechanical Dysfunction  
(Pancreatic Divisum, Sphincter of Oddi 
Dysfunction, Annular Pancreas) 
4  (57%) 3  (43%)  
 
Idiopathic Pancreatitis 2  (29%) 1  (14%)   
 
3.2 Subcutaneous Insulin Therapy 72 Hour Investigational Period 
 The results from the 72 hour investigational period (Table 7.) support Hypothesis 1 by 
showing that the average serum BG was significantly lower in the experimental group than in the 
control group (111±4 mg/dL v. 130±13 mg/dL; p=0.003).   In fact, the highest experimental 
group patient’s average BG was lower than the lowest control group patient’s average BG (Figure 
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5).  
 The standard deviation for the experimental group was lower than that for the control group 
(14.1±3.3 mg/dL v. 21.0±10.2 mg/dL; p=0.115), though with a p-value > 0.05.  This 
demonstrates a trend in support of Hypothesis 2 within this pilot study, showing that the effect 
was possibly underpowered but in the hypothesized direction.   
 
Table 7. Group Comparison for 72h Investigational Period (* indicates statistical significance 
with p < 0.05) 
  Control Group Experimental Group p-Value 
Serum BG Avg (mg/dL) 130 ± 13 111 ± 4 0.003 * 
Serum BG StDev (mg/dL) 21.0 ± 10.2 14.1 ± 3.3 0.115 
 Sensor BG Avg (mg/dL) 125 ± 20 114 ± 4 0.193 
 Sensor BG StDev (mg/dL) 21.0 ± 10.3 20.1 ± 5.1 0.848 
 % in Range 70-140 mg/dL (%) 70.6 (48.0, 93.1) 89.2 (83.5, 94.8) 0.074 
 Hypoglycemia 
        AUC < 70 mg/dL 
(min*mg/dL/day) 
1615 ± 4267 146 ± 270 0.381 
 
% < 70 mg/dL (%) 4.8 (-6.9, 16.6) 1.1 (-0.3, 2.6) 0.461 
 Hyperglycemia 
        AUC > 140 mg/dL 
(min*mg/dL/day) 
7860 ± 11444 2025 ± 1177 0.205 
 % > 140 mg/dL (%) 23.7 (1.5, 46.0) 9.7 (4.9, 14.5) 0.157 
 
         AM C-Peptide Avg (ng/mL) 1.6 ± 1.0 1.3 ± 0.6 0.443   
TDD of Insulin (U/kg/day) 0.56 ± 0.31 0.26 ± 0.17 0.040 * 
 
 The Area Under the Curve analysis showed lower values for the experimental group than 
for the control group for both hypoglycemia (146±270 min*mg/dL/day v. 1615±4267 
min*mg/dL/day; p=0.381) and hyperglycemia (2025±1177 min*mg/dL/day v. 7860±11444 
min*mg/dL/day; p=0.205).  While neither of these measures met the criteria for statistical 
significance, within this pilot study the trend was in the hypothesized direction.  The percent time 
in both hypoglycemia and hyperglycemia, also followed this trend.  These findings provide 
support for Hypothesis 3 that there appears to be less time spent in hyperglycemia and 
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hypoglycemia for the experimental group than for the control group.  Further support for this 
hypothesis comes from the fact that the experimental group was in the target range of 70-140 
mg/dL 89.2 % (83.5, 94.8) of the time and the control group was in range 70.6% (48.0, 93.1) of 
the time, a very clinically significant difference which was just outside the range of statistical 
significance for this study (p=0.074).  The findings also show that there is no evidence of 
significantly increased hypoglycemia in the experimental group than in the control group, an 
important safety consideration with more aggressive BG control. 
 There was no difference in AM C-peptide levels between the 2 groups during this study 
period.  The total daily insulin dose in the experimental group was significantly lower than in the 
control group (0.26±0.17 v. 0.56±0.31; p=0.040).  This is at least partially expected as it is often 
observed clinically that patients require 20% less insulin when delivery is continuous rather than 
intermittent.  
 
Figure 5. Serum Blood Glucose Values by Patient and Study Group.  Large circle denotes mean, 
box denotes 25th percentile, median and 75th percentile and small circles denote outliers. 
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3.3 Analysis for Confounders and Effect Modifiers 
 For the four a priori defined hypothesis testing endpoints of average serum BG, standard 
deviation of serum BG, AUC in hypoglycemia and AUC in hyperglycemia additional analysis 
was conducted to investigate for possible confounding or effect modification (Appendix 7.3).   
 As noted above, the average days on insulin drip, or days between surgery and beginning 
of the SQ insulin period, was significantly different between the two groups.  This raised concern 
for the possibility of this factor as a potential confounder for the differences observed between the 
2 groups.  Multiple least-squares regression analyses were conducted to look at the relationship 
between days on drip and study group effects on the 4 primary endpoints.  The data gave no sign 
that there is any effect of days on drip on the study group effects seen for these endpoints. 
  Due to their role in insulin secretion and BG regulation we hypothesized that the number 
of islets transplanted may be an effect modifier for all aspects of glucose regulation (Appendix 
8.3 and Figure 6.).  Islet yield was thus investigated using multiple least-squares regression 
analysis looking at the relationship between islet yield (IEq/kg) and study group effects on the 4 
primary endpoints.  Islet yield was a significant predictor of average serum BG (p=0.0188), 
standard deviation in serum BG (p=0.0340), and AUC in hyperglycemia (p=0.0164).  No effect 
was observed for AUC in hypoglycemia (p=0.8060).  Statistically significant interaction was 
observed for average serum BG (p=0.0348) and AUC in hyperglycemia (p=0.0145), and 
substantial interaction was observed for standard deviation of serum BG (p=0.0842).    
 More thorough analysis of the covariance plots reveals an apparent trend that islet yield had 
minimal effect on the experimental group but a marked effect on the control group with higher 
islet yield being correlated with lower average serum BG, standard deviation in serum BG and 
AUC in hyperglycemia.  While this pilot study was not intended to investigate this effect 
modifier, these observed effects warrant significant discussion as well as consideration in 
planning future phases of this research.  
 29 
 30 
 
3.4 Follow Up Visit Data 
 To date, all 14 participants have returned for 14 and 28 days post-surgery follow up for 
random BG and C-peptide testing.  No significant differences were observed between the two 
treatment groups for either random BG or C-peptide at 14 or 28 days post-surgery (Table 8.).   
 
Table 8. Follow Up Visit Data 
         Control Group Experimental Group p-Value 
Day 14 Post-TPIAT (n=14) 
        BG (mg/dL) 135 ± 81 108 ± 16 0.4012 
 C-peptide (ng/mL) 1.0 ± 0.9 1.6 ± 0.9 0.2208 
 
         Day 28 Post-TPIAT (n=14) 
        BG (mg/dL) 113 ± 29 100 ± 21 0.3258 
 C-Peptide (ng/mL) 1.0 ± 1.2 1.7 ± 1.2 0.3116 
 
         6 Months Post-TPIAT (n=5) 
        Hemoglobin A1c (%) 6.0 ± 0.1 6.0 ± 0.2 0.7663 
 TDD of Insulin (U/day) 7.0 ± 5.6 5.4 ± 0.7 0.6438 
 Fasting BG (mg/dL) 94 ± 1 90 ± 4 0.3339 
 Fasting C-Peptide (ng/mL) 0.8 ± 0.6 1.3 ± 0.8 0.4579 
 Peak C-Peptide (ng/mL) 3.8 ± 2.1 4.0 ± 3.3 0.9506 
  
 
The second aim of this study was to assess islet function at 6 months post-surgery.  To 
date, only 5 patients (3 experimental and 2 control) have reached the 6 month follow-up time 
point.  Interim analyses of the 6 month follow up endpoints do not reveal any significant 
differences between the two treatment groups.  Full assessment of hypothesis 4 is considered 
incomplete at this time as only 5 of 14 study participants (35.7%) have yet reached this follow up 
time point. 
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3.5 Safety Analysis 
 Due to the use of investigational medical technology in a research setting, this project 
required an extensive safety protocol (Appendix 7.1) and adverse event reporting guidelines 
(Appendix 7.2).  No participants in either group experienced a severe adverse event of grade 3 or 
greater.  No participants in either group required withdrawal from the investigational protocol for 
safety concerns.  One participant in the control group experienced a grade 2 event of seizure 
without hypoglycemia.  This was determined by the primary team to be a reaction to narcotic 
medications used for post-surgery pain control.  One participant in the control group experienced 
2 episodes of symptomatic hypoglycemia with BG values in the 50-60 mg/dL range and resolving 
with IV dextrose.  Two participants in the experimental group each experienced one episode of 
asymptomatic hypoglycemia documented in the 50-60 mg/dL range, resolved with IV dextrose; 
in review, both events appear to be related to incorrect device calibration.  A third patient 
received IV dextrose for a suspected hypoglycemic event (BG measured 50-60 mg/dL range) but 
was subsequently found to have diluted serum samples and in retrospective review this event was 
attributed to factious hypoglycemia.   
 The FDA required testing of serum ketone levels for all experimental patients at the end 
of the study period to ensure that no patients were in diabetic ketoacidosis at the end of the study.  
All patients had normal ketone levels (< 0.6 mmol/L) with only 2 of 7 having undetectable ketone 
levels and the overall average being 0.21±0.19 mmol/L. 
 
3.6 CGM Analysis 
 Sub-analysis of sensor performance of the Enlite 2 sensors in the 7 experimental patients 
was conducted correlating q30 minute reference YSI BG values with calibrated sensor readings 
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10 minutes later to construct a Clarke Error Grid (Figure 7. and Table 9.).  This analysis produced 
990 paired YSI-Sensor sets over 7 individual patients totaling 21 days of observations.  With 
regards to the Clarke Error analysis, sensor performance had 86.1% of all pairs in Zone A and 
99.4% of all pars in Zones A or B. 
Figure 7. Clarke Error Grid of CGM Function 
 
 
Table 9. Clarke Error Grid Analysis 
   
EGA Metrics 
Region 
 A B C D E Total 
Points 852 132 1 5 0 990 
% 86.1 13.3 0.1 0.5 0.0 100.0 
% A+B 99.4 
     
 
 33 
 Overall sensor analysis showed MARD of 11.0±11.5%, with substantial variability across 
different patients (Table 10).  Excluding the first 12 hours after sensor placement, the sensors 
were recalibrated an average of 8.3 times per day and the active sensor was switched an average 
of 1.4 times per day (Table 11.).  Average calibration factor across all patients was 7.692±3.786 
mg/nA*dL with an acceptable range being 1.5 to 20 mg/nA*dL. 
 
Table 10. Continuous Glucose Monitor Bias and Mean Absolute 
Relative Difference 
Patient 
Bias (mg/dL) ARD (%) 
Mean StDev Mean StDev 
CLTPIAT01 0.6 12.6 8.83 7.81 
CLTPIAT03 -3.3 17.1 10.45 10.27 
CLTPIAT05 -0.5 24.3 16.59 17.16 
CLTPIAT06 7.6 12.6 10.9 9.32 
CLTPIAT09 -1.3 16.7 10.94 10.62 
CLTPIAT11 4.7 13.7 10.18 9.09 
CLTPIAT13 -0.1 13.7 9.08 16.21 
OVERALL 1.1 15.8 11.0 11.5 
 
 
 
 
Table 11. Continuous Glucose Monitor Calibration Data 
Patient 
Cal Factor (mg/nA*dL) Recalibrations 
per 24 hr# 
Active Sensor 
Changes per 24 hr# Avg StDev 
CLTPIAT01 5.597 0.652 9.2 1.6 
CLTPIAT03 11.115 9.923 5.6 0.4 
CLTPIAT05 7.492 4.550 14.0 2.8 
CLTPIAT06 9.495 2.531 7.6 0.0 
CLTPIAT09 11.091 7.042 12.4 2.4 
CLTPIAT11 4.500 0.886 5.6 1.6 
CLTPIAT13 4.552 0.916 3.6 1.2 
AVERAGE 7.692 3.786 8.3 1.4 
# Over the 72 hour study period excluding the initial 12 hours 
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4.0 DISCUSSION 
 In patients with chronic pancreatitis, TPIAT is performed to alleviate pain and minimize 
the risk of long-term diabetes.  Success of islet engraftment is heavily dependent on maintenance 
of narrow-range euglycemia in the post-transplant period.  Closed loop insulin pump systems 
have never previously been used in islet transplant populations but have been shown to maintain 
narrow-range euglycemia in patients with type 1 diabetes.  This study aimed to assess the efficacy 
and feasibility of a CL system in patients after TPIAT.  Overall the pilot results from this efficacy 
and feasibility study support the effectiveness and safety of CL systems to improve glycemic 
control in the TPIAT population in the post-transplant period.   
 
4.1 Experimental Period Findings 
 The major goal of insulin therapy in the post-transplant period is to limit malglycemia 
during the immediate post-transplant period.  Malglycemia is the combined effect of 
hyperglycemia, hypoglycemia, and glycemic variability and has been shown in other cell 
transplant populations, notably hematopoietic cell transplant (HCT) patients, to have negative 
effects on post-transplant outcomes 78-80.   
 The overall effect of CL therapy was demonstrated in this study to be successful in 
reducing hyperglycemia with likely reduction in glycemic variability without negatively 
impacting hypoglycemia (Table 7. and Figure 5.).  The overall time in range of 89.2% (83.5, 
94.8) for the CL group compares favorably with other studies investigating overnight or fasting 
populations.  O’Grady and colleagues recently utilized a similar PID system overnight in 8 
patients with T1DM and found 84.5% time in target range of 70-144 mg/dL 59.  Elleri and 
colleagues used a MPC system overnight in patients with T1DM and found 82% time in target 
range of 71-145 mg/dL 53. 
 As noted earlier, the time from surgery to SQ conversion (days on insulin drip) was 
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significantly shorter for the CL group than for the control group (Table 6.).  This was likely 
attributable to the conversion process being driven by the experimental team in the CL group and 
by the endocrine service in the control group.  The experimental team, being very confident in the 
CL system, was more aggressive at pushing forward with the SQ transition whereas the endocrine 
service wanted to see stable IV insulin infusion rates for > 24 hours prior to giving insulin 
injections.  In our clinical practice it has been observed that BG is more difficult to control in the 
immediate post-operative period than farther out as stress hormone levels are higher, pain is more 
severe and more fluctuant and GI absorption of feeds is less stable.  For these reasons, we 
postulate that any bias from the experimental group transitioning to SQ earlier, should bias the 
results towards the null hypothesis.  Multiple least squares regression analysis did not reveal 
significant confounding from this difference as well. 
 The effect modification observed based on islet yield transplanted is perhaps the most 
striking finding of this pilot study (Figure 6.).  This sub-analysis shows that for the CL group 
there was no improvement in BG average, BG standard deviation or AUC in hyperglycemia with 
increased islet yield whereas for the control group higher islet yield was associated with lower 
values for these 3 glycemic markers.  We postulate that in the CL group more aggressive 
continuous insulin therapy was able to maintain near normo-glycemia allowing for significant 
islet cell rest and thus a lack of variation based on islet cell yield.  While for the control group 
intermittent insulin therapy relied somewhat on endogenous insulin production from transplanted 
islets to handle variations in glycemia with success of this effect based on transplanted islet cell 
mass; thus for the control group there was suboptimal islet rest during this period. 
  
4.2 CGM Performance 
 An important aspect of CL system performance is continuous glucose monitor 
performance.  This technology has been mainly designed for outpatient use among healthy 
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patients with type 1 diabetes.  In this study, CGMs were used in a post-surgical population.  CGM 
devices are recommended to be worn on the abdomen with the thigh being an alternate site.  
Concern arose among the investigators during this pilot investigation that transient edema could 
be markedly effecting the CGM sensor strength and contributing to more frequent recalibrations 
in this population.  For this reason a sub-analysis was conducted among the 7 CL patients looking 
at CGM performance during the 72 hour investigational period. 
 A traditional Clarke Error grid was constructed looking at relative agreement between 
calibrated sensor reading and reference YSI serum BG (Figure 7. and Table 9.).  This data 
demonstrated that with recalibration, Enlite 2 sensor performance in this population was very 
good with > 85% of values in Zone A and > 99% of values in Zones A or B.  Further analysis of 
Mean Absolute Relative Difference (MARD) between the reference and CGM values revealed 
relatively strong correlation at 11.0% MARD overall (Table 10.).   
 The other aspect to consider though is what level of supervisory rigor was required to 
achieve this level of system correlation.  Medtronic recommends a calibration factor for the Enlite 
2 in this system between 1.5 and 20 mg/nA*dL and recommends recalibration for 2 values in a 
row with an ARD of ≥20% or one value with an ARD of ≥ 30%.  To more closely replicate true 
clinical utility, sensors were placed in this study just prior to SQ transition rather than a day in 
advance, as is done in many other studies.  Sensors were frequently recalibrated during the first 
12 hours, considered the initial “settling time” for the sensor.  After the first 12 hours, sensors in 
this study were recalibrated an average of 8.3 times per day or roughly once every 3 hours, 
including overnight (Table 11.).  Furthermore the active sensor was switched 1.4 times per day.  
This level of rigor achieved a very good calibration factor of 7.692 mg/nA*dL across the entire 
investigational period.  It should be noted that this analysis is a post hoc investigation of pilot data 
and no protocols were in place during the study to minimize recalibrations or active sensor 
changes. 
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 Only within the past 1-2 years have publications been coming out which investigate the 
role of CGM technology in post-surgical populations, most often cardiac surgery patients.  A 
recent study from Siegelarr and colleagues investigated CGM use after cardiac surgery 81.  They 
found MARD values of 11% and 14% for the Navigator and Guardian sensors investigated.  They 
placed sensors on the abdomen the day before surgery and calibrated devices “according to the 
manufacturers’ instructions.”  No information on calibration factors was provided.  Saur and 
colleagues also investigated CGM after cardiac surgery using the Symphony CGM system and 
found 99.6% of readings in Zones A and B with a MARD of 12.3% 82.  They calibrated the 
sensors every 4 hours.  Schuster and colleagues have also recently published an analysis of CGM 
data in a broader SICU population and found a MARD of 15.9% with 71.3% of values in Zone A 
and 98.9% of values in Zones A and B 83.  Their study used only 3 calibrations per day.  Overall, 
the findings from this study reveal similar MARD and Zone A and B percentages though with 
somewhat higher calibration frequency than other recent studies. 
 
4.3 Follow Up Data 
 Analysis of the 14 and 28 day post-surgical follow up data did not reveal any significant 
differences between the two groups.  The 6 month follow up data is only partially collected and 
will not be complete until after initial publication of this study’s results.  We consider it unlikely 
that only 3 days of improved glycemic control, though both clinically and statistically significant 
in magnitude, would produce observable improvements in long term islet function or insulin 
requirements.  While such a study has never been conducted previously in islet transplant 
patients, this hypothesis is based on the limited findings from the Buckingham “metabolic study” 
which did not show improved beta-cell survival with intensive CL therapy shortly after diagnosis 
of type 1 diabetes 84. 
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4.4 Comments on Efficacy and Feasibility 
 Overall the CL system was very effective in controlling BG in a narrow range after TPIAT.  
This system produced lower average BG with increased percent time in range without increasing 
hypoglycemia when compared to conventional MDI therapy.  At this stage of device development 
clinical feasibility was significantly limited by the supervisory requirement for q30 min serum 
BG sampling for the CL patients as well as the need for constant device supervision by a trained 
medical provider.  The frequency of sensor recalibration at every 3-4 hours also limits overall 
clinical feasibility at this time.  The CL system was also found to be safe overall with no SAE’s in 
either group.  There were no episodes of symptomatic hypoglycemia in the CL group and the 
overall frequency of hypoglycemia requiring intervention was less than once per day in both 
study groups. 
 Since the initial design and implementation of this study, CL technology has continued to 
move forward with more recent experimental systems having the control algorithm housed on the 
insulin pump thereby removing an additional variable with potential for communication error.  In 
addition, next generation CGM sensors are advertised as being more stable and requiring fewer 
recalibrations.  The transmitters for these sensors will also communicate with low energy 
Bluetooth rather than RF signals, further reducing missed communication errors. 
 
4.5 Study Limitations 
 This study was conducted in adult patients receiving TPIAT at the University of 
Minnesota.  The findings from this pilot study may have limited generalizability to other post-
surgical populations or other transplant populations.  The overall islet mass transplanted in both 
study groups was relatively high (5432±2983 IEq/kg) and this may limit conclusions about 
glycemic control as it pertains to patients receiving lower islet yields.  The total number of 
patients in this study (14 overall with 7 in each group) compares favorably with other initial 
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device studies (Table 2.), though a larger sample size would likely improve the significance and 
generalizability of the findings.  The investigational period (72 hours at 6.0±1.4 days post-
surgery) was relatively short and is unlikely to produce long term islet survival differences 
between the two groups.  The time between surgery and SQ transition was significantly shorter in 
the experimental group than the control group, though statistical investigation of this difference 
did not reveal significant bias. 
 
4.6 Future Directions of This Work 
 This project was a successful pilot study of a CL system in adults after TPIAT showing 
improved glycemic control without increased hypoglycemia or safety concerns.  Now that this 
has been demonstrated future work involves testing a CL system in pediatric patients after 
TPIAT.  Future projects will also involve use of a subsequent generation of this system for a 
longer duration of therapy including an outpatient setting.  We will also continue to follow this 
investigational cohort of 14 patients at 6 months and likely 1 and 2 years post-surgery to look at 
rates of insulin independence between the two groups. 
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5.0 CONCLUSIONS 
 CL insulin systems are a valuable emerging tool for narrow range glycemic control in 
patients requiring insulin therapy.  This technology was shown in this study to provide 
statistically and clinically significant improvements in glycemic parameters in adults after total 
pancreatectomy with islet auto-transplantation without producing associated hypoglycemia or 
adverse events.  Continued improvements in these experimental systems, notably in CGM 
devices, will be essential towards moving this technology from experimentally effective to 
clinically feasible.  This technology has the ability to provide essential islet cell rest after 
transplantation and may play a role in long term islet survival. 
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7.0 Appendix 
7.1 Safety Monitoring Plan: 
Safety Monitoring Plan:  
To ensure patient safety, patients on the experimental CL device will have blood glucose checked 
by reference method of YSI device every 30 minutes (±15 min) throughout the entire 72 hour 
experimental period.  In addition, reference BG checks will occur under the following situations 
when hypoglycemia or hyperglycemia is suspected:  
A. Hypoglycemia  
1. If YSI glucose value falls below 80 mg/dL at any time:  
a) If YSI is 61-80 and BG was declining at <1 mg/dL/min in the previous 30 min, 
YSI will be checked every 15 minutes until YSI > 80. If glucose was declining at 
a rate >1 mg/dL/min in the previous 30 min, check YSI glucose every 5 minutes 
until YSI > 80.  
b) If YSI is 51-60 mg/dL, first treat hypoglycemia with oral or IV glucose. If the 
subject’s BG was declining at <1 mg/dL/min in the previous 30 min, check YSI 
every 15 minutes until YSI > 80. If glucose was declining at a rate >1 mg/dL/min 
in the previous 30 min, check YSI glucose every 5 minutes until YSI > 80.  
c) If YSI is ≤ 50 mg/dL first treat hypoglycemia with IV glucose or glucagon. 
Check YSI glucose every 5 minutes until BG starts to rise, and then every 15 
minutes until YSI > 80. The study should be stopped.  
2. If subjects experience any symptoms of hypoglycemia (e.g., shakiness, dizziness, 
sweating, hunger, pale skin color, moodiness, clumsiness, difficulty paying attention, or 
tingling around the mouth). Check YSI glucose values:  
a) If YSI > 80 mg/dL, continue with protocol and check YSI glucose every 30 
minutes.  
b) If YSI is 70-80 mg/dL and BG was declining at <1 mg/dL/min in the previous 30 
min, YSI should be checked every 15 minutes until YSI > 80. If glucose was 
declining at a rate >1 mg/dL/min in the previous 30 min, check YSI glucose 
every 5 minutes until YSI > 80.  
c) If YSI is 51-70 mg/dL, first treat hypoglycemia with oral or IV glucose. If the 
subject’s BG was declining at <1 mg/dL/min in the previous 30 min, YSI should 
be checked every 15 minutes until YSI > 80. If glucose was declining at a rate >1 
mg/dL/min in the previous 30 min, check YSI glucose every 5 minutes until YSI 
> 80.  
d) If YSI is ≤ 50 mg/dL, first treat hypoglycemia with IV glucose or glucagon. 
Check YSI glucose every 5 minutes until BG starts to rise, and then every 15 
minutes until YSI > 80. The study should be stopped.  
3. If subjects display signs of neuroglycopenia (e.g. lethargy, disorientation, confusion 
[disordered processing of information or communication], or inappropriate behavior) or 
severe hypoglycemic symptoms (e.g., hypoglycemic seizure, loss of consciousness, 
inability to properly consume treatment), first treat hypoglycemia with IV glucose or 
glucagon.  If YSI is ≤ 80 mg/dL, check YSI glucose every 5 minutes until BG starts to 
rise, and then every 15 minutes until YSI > 80. The study should be stopped.  
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B. Hyperglycemia  
If CGM or YSI glucose value is ≥ 250 mg/dL at any time, perform another YSI check.  
a) If YSI < 250 mg/dL, proceed with investigation and re-check YSI in 30 minutes.  
b) If YSI ≥ 250 mg/dL, in addition to a reference glucose check with YSI, check 
blood ketone levels every hour until YSI < 250 and ketones < 0.6 mmol/L.  
i. If ketones < 0.6 mmol/dL, continue the study but check the pump for 
occlusion and replace the infusion set if necessary.  
ii. If ketones ≥ 0.6 mmol/dL, the study should be stopped and the study 
physician will take over insulin dosing.  
c) If YSI ≥ 250 mg/dL for 2 hours or ≥400 mg/dL at any time, check YSI every 30 
minutes and check ketone level every hour until YSI < 250 and ketones < 0.6 
mmol/L. However, regardless of the ketone results, the study should be 
stopped and the study physician will take over insulin dosing.  
 
Study or Patient Termination 
Suspension of Closed Loop System  
Closed-loop control shall be suspended if the Investigator feels at any time subject safety is 
compromised.  Replacement of the insulin pump infusion set should be performed by the 
Investigator along with any concurrent open-loop adjustment of insulin pump settings deemed 
medically necessary by the Investigator.   In the unlikely event that diabetic ketoacidosis should 
develop, the closed-loop control shall be suspended immediately and the subject treated as 
medically necessary. 
 
Patient Termination 
Safety Stopping Rules:  
We will stop an individual patient’s study if any of the following occurs: 
• The subject had a serious adverse event deemed related to study.  
• Glucagon is required to treat hypoglycemia.  
• The subject experiences a hypoglycemic seizure.  
• The subject becomes unconscious due to hypoglycemia.  
• The subject has reference BG >250 mg/dL for 2 hours or ≥400 mg/dL at any time.  
• The subject has reference BG <50 mg/dL at any time.  
• The subject develops emesis, nausea or abdominal pain.  
• The subject develops decreased sensorium (sleepy, difficult to arouse) with or without 
emesis and glucose >350.  
• The subject develops ketones that are confirmed at > 0.6 mmol/L at any time.  
• The subject has a positive pregnancy test.  
• If there is no functional CGM transmitter and receiver for >2 hours. 
 
Study Termination 
If two patients require their study to be stopped based on the above criteria, the study will be 
stopped. 
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7.2 Adverse Event Grading and Reporting 
Grading of Adverse Events 
The term “adverse event” (AE) is defined as any untoward medical occurrence in a patient or 
clinical investigation subject administered a pharmaceutical product and which does not 
necessarily have to have a causal relationship with this treatment.   A serious adverse event (SAE) 
is any untoward medical occurrence at any dose that: results in death, is life-threatening, requires 
inpatient hospitalization or prolongation of existing hospitalization, results in persistent or 
significant disability/incapacity, or is a congenital anomaly/birth defect.  Each event will be 
analyzed to determine is relatedness to study intervention (definitely, probably, possibly, 
unlikely, or unrelated) and the severity will be graded as follows, modified from the Common 
Toxcity Criteria: 
• MILD (Grade 1) – transient or mild discomfort; no limitation in activity; no medical 
intervention required. 
• MODERATE (Grade 2) – mild to moderate limitation in activity, some assistance may 
be needed; no or minimal medical intervention/therapy required. 
• SEVERE (Grade 3) – marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalization is possible. 
• LIFE-THREATENING or DISABLING (Grade 4) – extreme limitation in activity, 
significant assistance required; significant medical intervention/therapy required, 
hospitalization or hospice care probable. 
• DEATH (Grade 5) – event is a direct cause of death. 
All adverse events will be graded as mild, moderate, or severe, according to the guidelines 
established in the current Common Terminology Criteria for Adverse Events (CTCAE). 
 
Serious Adverse Events (SAE) 
Defined as any adverse event that suggests a significant hazard, contraindication, side effect, or 
precaution. This includes, but may not be limited to any of the following events: 
1. Death: A death occurring during the study or which comes to the attention of the 
investigator during the protocol-defined follow-up after the completion of therapy, 
whether or not considered treatment-related, must be reported. 
2. Life-threatening: Any adverse therapy experience that places the patient or subject, in 
the view of the investigator, at immediate risk of death from the reaction as it occurred 
(i.e., it does not include a reaction that, had it occurred in a more serious form, might 
have caused death). 
3. In-patient hospitalization or prolongation of existing hospitalization. 
4. Persistent or significant disability or incapacity. 
5. Congenital anomaly/birth defect. 
6. Other serious (Important medical events). 
 
Documentation and Reporting of Adverse Events  
All AEs Grade 2 and greater that occur after the subject has received investigational intervention 
will be documented in the CRF and will include date of onset, date of resolution (if applicable), 
name or brief description of the event, treatment given for the event, severity, relationship to 
study drug, action taken with regard to study intervention, outcome, and whether the event was 
classified as serious.  A physician will determine the relationship of the event to the study.  SAEs 
will be reported to Medtronic within 48 hours (24 hours if fatal or life-threatening and at least 
possibly related to study drug).  SAE’s that are at least possibly related to therapy, unexpected, 
and severe will be reported within 10 days to the IRB.   A listing of all other adverse events will 
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be sent to the IRB and to Medtronic annually.  All unanticipated adverse device effects will also 
be reported to the FDA within 10 business days after first receipt of notice of the effect.  
Thereafter additional reports will be provided concerning the effect as the FDA requests. 
 
Data and Safety Monitoring Plan 
For this pilot study the investigators will monitor patients throughout the 72 hour investigational 
period.  Participants will be wearing a continuous glucose monitor which will provide continuous 
BG data for both closed-loop and conventional therapy patients.  In addition patients on closed 
loop systems will have YSI BG values tested at least every 30 minutes.  A research nurse will be 
in house with all patients on closed-loop systems and the PI or a co-investigator will be available 
at the hospital during weekdays and via pager on nights and weekends.  Daily blood glucose 
values will be monitored and insulin levels adjusted for all conventional therapy patients as part 
of routine care.  For closed-loop patients, blood glucose data will be continuously reviewed by 
the research nurse as part of the experimental protocol.   
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7.3 Analysis for Confounding and Interaction 
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